Loading clinical trials...
Loading clinical trials...
A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB002 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Conditions
Interventions
GB002
Placebo
+1 more
Locations
14
United States
UCSD Medical Center
La Jolla, California, United States
University of California Davis Medical Center
Sacramento, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Yale New Haven Hospital
New Haven, Connecticut, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Norton Pulmonary Specialists
Louisville, Kentucky, United States
Start Date
February 4, 2020
Primary Completion Date
May 5, 2021
Completion Date
May 5, 2021
Last Updated
September 1, 2021
NCT07218029
NCT07120789
NCT06649110
NCT04778046
NCT06481852
NCT06477640
Lead Sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions